10-Q/A: DIH Holding US, Inc. Restates Q1 2025 Financials Due to Revenue Recognition Errors

DIH Holding US, Inc. has amended its first quarter 2025 financial report to correct errors in revenue and cost of sales recognition, as well as other immaterial classifications.

Summary

• DIH Holding US, Inc. has restated its financial statements for the quarter ended June 30, 2024, due to errors in revenue and cost of sales recognition.
• The restatement was triggered by the identification of errors in the timing of revenue recognition for two devices that were sold in June 2024 but recognized in July 2024.
• Additionally, immaterial errors related to the classification of cost of sales, other income (expense), and the classification of warrants were corrected.
• The company's revenue increased by 30% to $16.96 million for the three months ended June 30, 2024, compared to $13.045 million for the same period in 2023.
• The net loss for the quarter was $0.31 million, an improvement from the $2.913 million loss in the same period last year.
• The company had $2.7 million in cash and cash equivalents as of June 30, 2024.
• The company issued $3.3 million in convertible debentures with a discount of $300 thousand, resulting in net proceeds of $2.5 million.
• The company's accumulated deficit was $35.5 million as of June 30, 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While the company shows strong revenue growth and improved profitability, the need for a restatement and the identification of material weaknesses in internal controls raise concerns. The company's ongoing losses and accumulated deficit also contribute to the negative sentiment.

Positives

• Revenue increased by 30% year-over-year, indicating strong sales growth.
• The net loss significantly improved, suggesting better cost management and operational efficiency.
• The company secured $2.5 million in net proceeds from convertible debentures, bolstering its liquidity.
• Gross profit increased by 75.2% year-over-year, indicating improved profitability on sales.
• The company is taking steps to streamline its organization and cost structure.

Negatives

• The company had to restate its financial statements due to errors in revenue recognition, indicating weaknesses in internal controls.
• The company continues to operate at a loss, with a net loss of $0.31 million for the quarter.
• The company has an accumulated deficit of $35.5 million, highlighting past financial challenges.
• The company had negative cash flows from operating activities of $2.0 million for the quarter.
• The company has a material weakness in internal controls over financial reporting.

Risks

• The company faces ongoing supply chain and inflation challenges that could impact costs and timelines.
• Fluctuations in foreign currency exchange rates could affect reported revenues and profitability.
• The company is exposed to risks associated with the implementation of the EU MDR.
• The company's operations are exposed to various global macroeconomic factors, including the impact of conflict in Ukraine, conditions related to the COVID-19 pandemic, supply chain disruption, higher interest rates and inflationary pressures.
• The company has a material weakness in internal controls over financial reporting.

Future Outlook

The company plans to continue to fund its growth through cash flows from operations and future debt and equity financing, and believes that its current cash and cash equivalents, together with cash provided by operating activities, will provide adequate liquidity through one year from the date that these condensed consolidated financial statements are issued.

Management Comments

• Management believes that the financial statements included in this Annual Report present fairly in all material respects our financial position, results of operations and cash flows for the periods presented.
• Management expects that its cash and cash equivalents, together with cash provided by our operating activities and proceeds from future debt and equity financings, will be sufficient to fund its operating expenses and capital expenditures requirements for at least the next 12 months.

Industry Context

The company operates in the medical rehabilitation device industry, which is subject to regulatory changes and technological advancements. The company's performance is influenced by factors such as healthcare spending, technological innovation, and regulatory compliance. The restatement and the need to improve internal controls highlight the challenges of operating in a regulated industry.

Comparison to Industry Standards

• While the document does not provide specific industry benchmarks, companies like Ekso Bionics and ReWalk Robotics are also involved in robotic rehabilitation and face similar challenges in terms of regulatory approvals, market adoption, and financial sustainability.
• Ekso Bionics reported a revenue of $3.8 million in Q1 2024, while ReWalk Robotics reported $1.5 million in Q1 2024, making DIH's $16.96 million revenue in Q1 2025 significantly higher.
• However, both Ekso Bionics and ReWalk Robotics have also reported net losses, which is consistent with DIH's current financial situation.
• The need for restatement and the identification of material weaknesses in internal controls are not uncommon in the medical device industry, especially for companies that have recently gone public or are undergoing rapid growth.

Related Party Transactions

• The company has related party transactions with DIH Cayman, DIH Hong Kong, Hocoma AG, and Motek Group.
• The company has three notes payable to Hocoma AG, due on June 30, 2026, with an interest rate of 1.25%.
• The company has a distribution agreement with Motek Group, where it acts as the exclusive distributor of Motek's products.

Stakeholder Impact

• Shareholders may be concerned about the restatement and the material weakness in internal controls.
• Employees may be affected by the company's efforts to streamline its organization and cost structure.
• Customers may experience delays due to supply chain issues.
• Creditors may be impacted by the company's debt obligations and financial performance.

Next Steps

• The company will continue to implement measures to improve internal controls over financial reporting.
• The company will continue to work on the implementation of its remediation plan.
• The company will continue to monitor and address supply chain and inflation challenges.
• The company will continue to fund its growth through cash flows from operations and future debt and equity financings.

Key Dates

Keywords

financial restatement, revenue recognition, convertible debt, medical devices, rehabilitation, internal controls, supply chain, foreign exchange, EU MDR